What is the 13F Pro Quality Score for RGEN?

13F Pro ranks REPLIGEN CORP (RGEN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RGEN's current score at https://13fpro.ai/research/RGEN (free sign-up required for the full ranking).

Which hedge funds own the most RGEN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RGEN include BlackRock,, FMR, UNITED CAPITAL FINANCIAL ADVISORS,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RGEN as soon as new 13F filings post.

Where does 13F Pro source RGEN data?

All REPLIGEN CORP fundamentals and ownership data come directly from SEC EDGAR. REPLIGEN CORP files with the SEC under CIK 730272. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RGEN in?

REPLIGEN CORP (RGEN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RGEN research updated on 13F Pro?

RGEN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

REPLIGEN CORP(RGEN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 730272 RGEN stock profile & AI dashboard →

13F Pro Quality Score

54.1/100

Rank #1,238 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

62.7/100

Profitability

62.4/100

Balance Sheet

48.1/100

Earnings Quality

25.9/100

Free Cash Flow

70.5/100

Institutional Flow

42.2/100

Revenue Scale

43.6/100

Dilution Risk

27.6/100

RGEN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for REPLIGEN CORP (RGEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RGEN at 54.1/100 on a 32-signal composite quality model, placing it at rank #1,238 of 2,879 stocks — the top half of the AI-ranked universe. Areas of concern include earnings quality (25.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), REPLIGEN CORP reports quarterly revenue of $194.3M, net income of $8.3M, an operating margin of 8.2%. Top institutional holders of RGEN by reported 13-F value include BlackRock,, FMR, UNITED CAPITAL FINANCIAL ADVISORS,, based on the most recent SEC filings. RGEN trades on the Nasdaq exchange and files with the SEC under CIK 730272. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REPLIGEN CORP directly from SEC EDGAR. REPLIGEN CORP's 13F Pro composite quality score has ranged between 8 and 68 since 2023, currently 54.1 — a declining long-term trajectory across 47 quarterly and live scoring snapshots.

✦

Fun facts about REPLIGEN CORP

Quirks, history, and lore behind RGEN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life sciences company · mid-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of roughly $700–800 million, built almost entirely on selling hardware and consumables to biopharmaceutical manufacturers rather than making drugs itself.
3
The History
Founded in the 1980s, it spent decades as a quiet niche supplier before the biologics manufacturing boom turned it into a Wall Street darling in the 2010s.
4
The Secret
It doesn't cure patients — it sells the filtration, chromatography, and process equipment that drugmakers use to purify biologics; think of it as selling picks and shovels to the biotech gold rush.
5
The Lore
Its products sit inside the single-use bioprocessing workflow that makes mRNA vaccines and monoclonal antibodies possible — COVID-era demand sent its stock soaring well over 300% in just a few years.
6
The Giveaway
Its ticker rhymes with 'rigen,' its name evokes replication at a cellular level, and if a major pharma plant is purifying a biologic drug anywhere on Earth, there's a good chance this company's filtration membrane is doing the work.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$194.3M

Net Income

Q1 2026

$8.3M

Free Cash Flow

Q1 2026

$23.6M

Operating Margin

Q1 2026

8.2%

ROIC

Q1 2026

0.6%

D/E Ratio

Q1 2026

0.26

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+73.2% YoY

$634.4MFY 2024

FY18 $194.0MFY19 $270.2MFY20 $366.3MFY24 $634.4M

Net Income

-142.6% YoY

$-25.5MFY 2024

FY18 $16.6MFY19 $21.4MFY20 $59.9MFY24 $-25.5M

Operating Income

-150.3% YoY

$-35.1MFY 2024

FY18 $26.0MFY19 $36.1MFY20 $69.8MFY24 $-35.1M

EPS (Diluted)

-141.4% YoY

$-0.46FY 2024

FY18 $0.37FY19 $0.44FY20 $1.11FY24 $-0.46

Total Assets

+48.7% YoY

$2.83BFY 2024

FY18 $774.6MFY19 $1.40BFY20 $1.90BFY24 $2.83B

Total Debt

$525.6MFY 2024

FY18 —FY19 —FY20 —FY24 $525.6M

Op. Cash Flow

+180.1% YoY

$175.4MFY 2024

FY18 $32.8MFY19 $67.2MFY20 $62.6MFY24 $175.4M

Metric	FY 2024	FY 2020	FY 2019	FY 2018	FY 2017	FY 2015
Revenue	$634.4M +73.2%	$366.3M +35.5%	$270.2M +39.3%	$194.0M +37.4%	$141.2M +69.1%	$83.5M
Net Income	$-25.5M -142.6%	$59.9M +179.9%	$21.4M +28.8%	$16.6M -41.4%	$28.4M +203.4%	$9.3M
Operating Income	$-35.1M -150.3%	$69.8M +93.5%	$36.1M +38.8%	$26.0M +85.6%	$14.0M +1.8%	$13.8M
EPS (Diluted)	$-0.46 -141.4%	$1.11 +152.3%	$0.44 +18.9%	$0.37 -48.6%	$0.72 +157.1%	$0.28
Total Assets	$2.83B +48.7%	$1.90B +35.9%	$1.40B +80.7%	$774.6M +4.2%	$743.5M +408.4%	$146.2M
Total Debt	$525.6M	—	—	—	—	—
Operating Cash Flow	$175.4M +180.1%	$62.6M -6.8%	$67.2M +105.1%	$32.8M +87.8%	$17.5M	—

AI Insight: RGEN Financial Trends

Revenue growth stalling after strong 2025 rebound, but operating margins stabilizing near 8% and debt modest relative to equity base.

• Revenue grew 24% from Q2 2024 ($159M) to Q4 2025 ($198M), then declined 2% in Q1 2026 to $194M.

• Operating income swung from -$37M loss in Q4 2024 to consistent $14–18M profit in Q3 2025–Q1 2026.

• Operating cash flow averaged $33M across last four quarters, ranging $15–48M with no clear trajectory.

⚠ Q1 2026 revenue decline breaks eight-quarter growth streak; reversal warrants confirmation in coming quarters.

⚠ Operating cash flow fell 42% from Q3 2025 ($48M) to Q1 2026 ($28M) despite stable operating income.

⚠ Total debt jumped from unrecorded in Q2 2024 to $547M in Q1 2026; debt-to-equity ratio now 26%.

AI Insight: RGEN Ratio Trends

Repligen stabilized profitability after Q4 2024 collapse, but Q1 2026 shows signs of deceleration with margins and returns retreating from recent highs.

• Operating margin recovered from -21.8% in Q4 2024 to 8.2% in Q1 2026, signaling successful turnaround from operational crisis.

• Net profit margin fell to 4.3% in Q1 2026 from 8.2% peak in Q2 2025; NPM now lowest since Q3 2024 trough.

• ROIC stabilized near 2.4–2.7% range across last four quarters; leverage held steady at 0.26 D/E.

⚠ Net profit margin compression in Q1 2026 despite stable operating margin suggests cost-of-goods or tax headwinds; monitor Q2 sustainability.

⚠ ROE and ROA both declined in Q1 2026 versus Q4 2025, breaking uptrend; first quarterly decline in four quarters.

Get alerted when RGEN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for REPLIGEN CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RGEN

BlackRock, Inc.
$706.1M5,993,054 sh
FMR LLC
$340.1M2,886,786 sh
UNITED CAPITAL FINANCIAL ADVISORS, LLC
$326.8M2,773,980 sh
VANGUARD CAPITAL MANAGEMENT LLC
$282.4M2,396,511 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$271.6M2,305,094 sh
STATE STREET CORP
$209.4M1,777,285 sh
Bank of New York Mellon Corp
$180.4M1,531,402 sh
MAVERICK CAPITAL LTD
$178.9M1,518,805 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$164.7M1,397,515 sh
Invesco Ltd.
$150.6M1,278,255 sh

Fund	Value	Shares
BlackRock, Inc.	$706.1M	5,993,054
FMR LLC	$340.1M	2,886,786
UNITED CAPITAL FINANCIAL ADVISORS, LLC	$326.8M	2,773,980
VANGUARD CAPITAL MANAGEMENT LLC	$282.4M	2,396,511
VANGUARD PORTFOLIO MANAGEMENT LLC	$271.6M	2,305,094
STATE STREET CORP	$209.4M	1,777,285
Bank of New York Mellon Corp	$180.4M	1,531,402
MAVERICK CAPITAL LTD	$178.9M	1,518,805
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$164.7M	1,397,515
Invesco Ltd.	$150.6M	1,278,255

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RGEN on your watchlist

Track score changes the day REPLIGEN CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RGEN a good stock to buy?

13F Pro's AI-powered analysis of REPLIGEN CORP (RGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RGEN are available on the RGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RGEN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REPLIGEN CORP's investment landscape.